ARVAC vaccine: the last section of phase 2/3 begins and volunteers are called
The ARVAC Cecilia Grierson vaccine, designed to protect against the SARS-CoV-2 variants circulating in the region, begins the final stage of the call for volunteers concerning the last stretch of phase 2/3 clinical trials. In this stage, the safety and immunogenicity of three ARVAC formulas -including a bivalent version against Ómicron- will be evaluated in … Read more